Mirae Asset Global Investments Co. Ltd. Acquires 12,144 Shares of Moderna, Inc. $MRNA

Mirae Asset Global Investments Co. Ltd. grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 18.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 77,183 shares of the company’s stock after purchasing an additional 12,144 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Moderna were worth $2,276,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of MRNA. Legal Advantage Investments Inc. purchased a new position in Moderna in the 3rd quarter worth approximately $1,244,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Moderna in the 3rd quarter worth approximately $2,351,000. Douglas Lane & Associates LLC grew its stake in Moderna by 14.4% in the 4th quarter. Douglas Lane & Associates LLC now owns 1,291,465 shares of the company’s stock worth $38,085,000 after buying an additional 163,031 shares in the last quarter. CWM LLC grew its stake in Moderna by 50.1% in the 3rd quarter. CWM LLC now owns 390,333 shares of the company’s stock worth $10,082,000 after buying an additional 130,200 shares in the last quarter. Finally, Banco Santander S.A. grew its stake in Moderna by 22.1% in the 3rd quarter. Banco Santander S.A. now owns 215,894 shares of the company’s stock worth $5,577,000 after buying an additional 39,056 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Piper Sandler boosted their price target on shares of Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, February 23rd. Evercore set a $35.00 price objective on shares of Moderna in a research note on Tuesday, February 17th. BMO Capital Markets raised shares of Moderna from a “market perform” rating to a “buy” rating in a research note on Monday, January 12th. Jefferies Financial Group set a $37.00 price objective on shares of Moderna and gave the company a “hold” rating in a research note on Tuesday, March 3rd. Finally, Barclays upped their price objective on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a research note on Thursday, April 2nd. Two equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $33.87.

Moderna Price Performance

Shares of Moderna stock opened at $55.60 on Thursday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $59.55. The stock has a market capitalization of $21.96 billion, a price-to-earnings ratio of -7.65 and a beta of 1.33. The company has a fifty day moving average of $51.31 and a 200-day moving average of $38.49. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, beating the consensus estimate of ($2.79) by $0.68. The business had revenue of $678.00 million during the quarter, compared to analysts’ expectations of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The firm’s revenue for the quarter was down 33.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.91) EPS. Equities research analysts expect that Moderna, Inc. will post -6.99 EPS for the current year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: EU grants marketing authorization for mCOMBRIAX (COVID?19 + influenza combination) for adults 50+, marking the first authorized flu + COVID combo and backed by strong Phase 3 data—clearly the top near?term commercial catalyst. Article Title
• Positive Sentiment: Moderna initiated a Phase 3 study of its investigational mRNA pandemic influenza vaccine (mRNA?1018) with CEPI support—adds potential future revenue and strategic public?health partnerships. Article Title
• Positive Sentiment: Late?stage (Phase 3) trial of Moderna’s bird?flu mRNA vaccine has started in the U.S. and U.K., the first pandemic bird?flu mRNA vaccine to reach late?stage testing—strengthens pipeline breadth. Article Title
• Positive Sentiment: Moderna advanced mRNA?1018 to Phase 3 for bird flu and reported safety/effectiveness signals for repeat dosing of its seasonal mRNA candidate (mRNA?1010) at ESCMID/other meetings—clinical data momentum across respiratory programs. Article Title
• Neutral Sentiment: Moderna will present data at ASCO and is scheduled for several investor conferences in May (BofA, RBC, Bernstein)—events that could provide incremental updates but are uncertain catalysts. Article Title
• Neutral Sentiment: Market commentary noted Moderna outperforming broader returns today—reflects investor focus on the approval/trial headlines rather than a fundamental earnings revision. Article Title
• Neutral Sentiment: Report that HHS cancelled some funding while Moderna moved ahead with a bird?flu trial highlights mixed funding/backstop dynamics—company is progressing but external funding risks remain. Article Title
• Negative Sentiment: Despite these program wins, Moderna remains unprofitable with negative net margins and year?over?year revenue declines, and analysts still model negative EPS—limiting upside unless authorizations convert to material sales growth.

Insiders Place Their Bets

In other Moderna news, President Stephen Hoge sold 160,009 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the completion of the sale, the president owned 1,457,427 shares of the company’s stock, valued at $71,180,734.68. This represents a 9.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 10.80% of the stock is owned by insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.